The Clinical Biochemistry of the Menopause and Hormone Replacement Therapy

Report of a WHO Scientific Group. Research on the menopause. In: WHO Technical Report, Series 670. Geneva: WHO, 1981.

Treloar AE Boynton RE Behn BG Brown BW . Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967; 12: 77–126.

Khaw KT . Epidemiology of the menopause. Br Med Bull 1992; 48: 249–61.

Richardson SJ Nelson JF . Follicular depletion during the menopausal transition. Ann NY Acad Sci 1990; 592: 13–20.

Sturdee D Brincat M . The hot flush. In: Studd JW Whitehead MI , eds. The Menopause. Oxford: Blackwell Scientific Publications, 1988: 24–42.

Caspar RF Yen SSC . Menopausal flushes: Effect of pituitary gonadotrophin desensitization by a potent lutenizing hormone-releasing factor agonist. J Clin Endocrinol Metab 1981; 53: 1056–8.

Compston JE . HRT and osteoporosis. Br Med Bull 1992; 48: 309–44.

Lindsay R Aitken JM Anderson JB Hart DM MacDonald EB Clark AC . Longterm prevention of postmenopausal osteoporosis by oestrogen. Lancet 1976; i: 1038–41.

Rosenberg L Hennekens CH Rosner B . Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981; 139: 47–51.

Matthews RA Meilahn E Kuller LH Kelsey SF Caggiula AW Wing RR . Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321: 641–6.

Colditz GA Willett WC Stampfer MJ Rosner B Speizer FE Hennekens CH . Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316: 1105–10.

L'Hermite M . Risks of estrogens and progestogens. Maturitas 1990; 12: 215–46.

Rannevik GK Carlstrom SJ Jeppsson S Bjerre B Svanberg L . A prospective long-term study in women from pre-menopause to post-menopause: Changing profiles of gonadotropins, oestrogens and androgens. Maturitas 1986; 8: 297–307.

Sherman BM West JH Korenman SG . The menopausal transition: Analysis of LH, FSH, oestradiol and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab 1976; 42: 629–36.

Metcalf MG Donald RA Livesey JH . Pituitary ovarian function in normal women during the menopausal transition. Clin Endocrinol 1981; 14: 245–55.

Metcalf MG Donald RA Livesey JH . Pituitary-ovarian function before, during and after the menopause: A longitudinal study. Clin Endocrinol 1982; 17: 489–94.

Metcalf MG . The approach of menopause: A New Zealand study. N Z Med J 1988; 101: 103–6.

Lenton EA Sexton L Lee S Cooke ID . Progressive changes in LH and FSH and LH: FSH ratio in women throughout reproductive life. Maturitas 1988; 10: 35–43.

Ushiroyama T Yoshikawa M Saeki M Okuda K Sugimoto O . Hypergonadotropinemia with oestradiol secretion in peri- and post-menopausal period. Acta Obstet Gynecol Scand 1989; 68:139–43.

Lee SJ Lenton EA Sexton L Cooke ID . The effect of age on the cyclical patterns of plasma LH, FSH, oestradiol and progesterone in women with regular menstrual cycles. Hum Reprod 1988; 3: 851–5.

Chakravarti S Collins WP Thom MH Studd JWW . Relation between plasma hormone profiles, symptoms, and response to oestrogen treatment in women approaching the menopause. BMJ 1979; i: 983–5.

MacNaughton J Banah M McCloud P Hee J Burger H . Age related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age. Clin Endocrinol 1992; 36: 339–45.

Burger HG Igarashi M . Inhibin: Definition and nomenclature, including related substances. J Clin Endocrinol Metab 1988; 66: 885–6.

Sherman BM Korenman SG . Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest 1975; 55: 669–706.

Van look PFA Lothian H Hunter WM Michie EA Baird DT . Hypothalamic-pituitary-ovarian function in perimenopausal women. Clin Endocrinol 1977; 7: 13–31.

Scott RT Toner JP Muasher SJ Oehninger S Robinson S Rosenwaks Z . Follicle stimulating hormone levels on cycle day 3 are predictive of in vitro fertilisation outcome. Fertil Steril 1989; 51: 651–4.

Khalifa E Toner JP Muasher SJ Acosta AA . Significance of basal follicle stimulating hormone levels in women with one ovary in a program of in vitro fertilisation. Fertil Steril 1992; 57: 835–9.

Kaufert PA Gilbert P Tate R . Defining menopausal status: The impact of longitudinal data. Maturitas 1987; 9: 217–26.

Yen SSC Llerena O Pearson OH Littel AS . Disappearance rates of endogenous follicle-stimulating hormone in serum following surgical hypophysectomy in man. J Clin Endocrinol Metab 1970; 30: 325.

Trevoux R DeBrux J Castavier M Nahoul K Soule JP Scholler R . Endometrium and plasma hormone profile in the peri-menopause and post-menopause. Maturitas 1986; 8: 309–26.

Chakravarti S Collins WP Forecast JD Newton JR Oram DH Studd JWW . Hormone profiles after the menopause. BMJ 1976; 2: 784–6.

Woolf PD Hamil RW McDonald JV Lee LA Kelly M . Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab 1985; 60: 444–50.

Quint AR Kaiser FE . Gonadotrophin determinations and thyrotropin-releasing hormone and luteinizing hormone-releasing hormone testing in critically ill post-menopausal women with hypothyroxinemia. J Clin Endocrinol Metab 1985; 60: 464–71.

Gosden RG In: Biology of Menopause. London: Academic Press, 1985: 27–33.

Longcope C . Hormone dynamics of the menopause. Ann NY Acad Sci 1990; 592: 21–30.

Judd HL Shamonki IM Frumar AM Lagasse LD . Origin of serum oestradiol in postmenopausal women. Obstet Gynecol 1982; 59: 680–6.

Longcope C Hui SL Johnston CC . Free oestradiol, free testosterone, and sex hormone binding globulin in perimenopausal women. J Clin Endocrinol Metab 1987; 64: 513–18.

Chang RJ Judd HL . The ovary after the menopause. Clin Obstet Gynecol 1981; 24: 181.

Moraes MDE Jones GS . Premature ovarian failure. Fertil Steril 1967; 18: 440–61.

Ribot C Pouilles JM Bonneu M Tremollieres F . Assessment of the risk of postmenopausal osteoporosis using clinical factors. Clin Endocrinol 1992; 36: 225–8.

Rebar RW . Hypergonadotropic amenorrhoea and premature ovarian failure. A review. J Reprod Med 1982; 27: 179–86.

Siddle NC Sarrell P Whitehead MI . The effect of hysterectomy on the age of ovarian failure: Identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil Steril 1987; 47: 94–100.

Metcalf MG Braiden V Livesey JH . Retention of normal ovarian function after hysterectomy. J Endocrinol 1992; 135: 597–602.

Beastall GH Ferguson KM O'Reilly DStJ Seth J Sheridan B . Assays for follicle stimulating hormone and luteinising hormone: Guidelines for the provision of a clinical biochemistry service. Ann Clin Biochem 1987; 24: 246–62.

Marsh MS Whitehead MI . Management of the menopause. Br Med Bull 1992; 48: 426–57.

O'Herlihy C Pepperell RJ Evans JH . The significance of FSH elevation in young women with disorders of ovulation. BMJ 1980; 281: 1447–50.

Cohen BL Katz M . Further studies on pituitary and ovarian function in women receiving hormonal contraception. Contraception 1981; 24: 159–73.

Jung Hoffman C Heidt F Khul H . Effect of two oral contraceptives containing 30 microgram ethinyl oestradiol and 75 microgram oestrogene or 150 microgram desogestrel upon various hormonal parameters. Contraception 1988; 38: 593–603.

Von Schoultz B . Potency of different oestrogen preparations. In: Studd JW Whitehead MI , eds. The Menopause. Oxford: Blackwell Scientific Publications, 1988: 130–7.

Whitehead MI Godfree V In: Hormone Replacement Therapy: Your Questions Answered. Edinburgh: Churchill Livingstone, 1992: 217–18.

Burgay GT Vessey MP McPherson CK . Study of symptoms in middle life with special reference to the menopause. BMJ 1980; ii: 181–3.

McKinlay SM Jeffreys M . The menopausal syndrome. Br J Prev Soc Med 1974; 28: 108–15.

Robinson S Rodin DA Deacon A Wheeler MJ Clayton RN . Which hormone tests for the diagnosis of polycystic ovary syndrome? Br J Obstet Gynaecol 1992; 99: 232–8.

Zakut H Zer J Bernstein D . A new biological carrier for follicle stimulating hormone: An aid for the diagnosis of menopause. Gynecol Endocrinol 1987; i: 263–8.

BMA. Sex Hormones (Section 6.4). In: British National Formulary. London: British Medical Association and The Pharmaceutical Press, 1992: 267–73.

Naessen T Persson I Adami HO Bergstrom R Bergkvist L . Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann Intern Med 1990; 113: 95–103.

Law MR Wald NJ Meade TW . Strategies for prevention of osteoporosis and hip fracture. BMJ 1991; 303: 453–9.

Stampfer MJ Willett WC Colditz GA Rosner B Speizer FE Hannekens CH . A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985; 313: 1044–9.

Bush TL Barrett-Connor E Cowan LD Criqui MH Wallace RB Suchindran CM Cardiovascular mortality and non-contraceptive use of estrogen in women: Results from the Lipid Research Clinics programme follow-up study. Circulation 1987; 75: 1102–9.

Hunt K Vessey M . The risks and benefits of hormone replacement therapy: An updated review. Curr Obstet Gynecol 1991; 1: 21–7.

Beaglehole R . Oestrogens and cardiovascular disease. BMJ 1988; 297: 571–2.

Paterson M . A randomised double-blind cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles. Br J Obstet Gynaecol 1982; 89: 464–72.

Hunt K Vessey M McPherson K Coleman M . Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987; 94: 620–35.

Smith DC Prentice R Thompson DJ Herrmann W . Association of exogenous estrogen and endometrial cancer. N Engl J Med 1975; 293: 1164–7.

Padwick ML Pryse-Davies J Whitehead MI . A simple method for determining the optimal dosage of progestin in post-menopausal women receiving estrogens. N Engl J Med 1986; 315: 930–4.

Whitehead MI Lobo RA . Progestogen use in postmenopausal women. Lancet 1988; ii: 1243–4.

Whitehead MI Hillard TC Crook D . The role and use of progestogens. Obstet Gynecol 1990; 75: 59S–76S.

Grady D Ernster V . Invited commentary: Does postmenopausal hormone therapy cause breast cancer? Am J Epidemiol 1991; 134: 1396–400.

Whitehead MI Fraser D . Controversies concerning the safety of estrogen replacement therapy. Am J Obstet Gynecol 1987; 156: 1313–22.

Jacobs HS Loeffler FE . Postmenopausal hormone replacement therapy. BMJ 1992; 305: 1403–8.

Cardozo LD . Routes of Oestrogen Administration. In: Studd JW Whitehead MI , eds. The Menopause. Oxford: Blackwell Scientific Publications, 1988: 138–45.

Balfour JA Heel RC . Tansdermal Estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990; 40: 561–82.

Kuhl H . Pharmacokinetics of oestrogens and progestogens. Maturitas 1990; 12: 171–97.

Gangar K Cust M Whitehead MI . Symptoms of oestrogen deficiency associated with supraphysiological plasma oestradiol concentrations in women with oestradiol implants. BMJ 1989; 299: 601–2.

Meade TW Berra A . Hormone replacement therapy and cardiovascular disease. Br Med Bull 1992; 48: 276–308.

Chetkowski RJ Meldrum DR Steingold KA Randle D Lu JK Eggena P Biologic effects of transdermal oestradiol. N Engl J Med 1986; 314: 1615–20.

Ellerington MC Whitcroft SIJ Whitehead MI . HRT: Developments in therapy. Br Med Bull 1992; 48: 401–25.

Oral contraception in the perimenopause [Editorial]. Drug Ther Bull 1991; 29: 3–4.

Powers MS Schenkel L Darley PE Good WR Balestra JC Place VA . Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17beta-estradiol: Comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985; 152: 1099–106.

Wilkes HC Meade TW . Hormone replacement therapy in general practice: A survey of doctors in the MRC's general practice research framework. BMJ 1991; 302: 1317–20.

Nisbet JA Jomain PA . Discrepancies in plasma estradiol values obtained with commercial kits. Clin Chem 1987; 33: 1672.

Lichtenberg V Schulte-Baukioh A Lindner C Braendle W . The results of serum estradiol-17-β (E2) determination from women receiving estrogen replacement therapy are discrepant using different immunoassay-kits (German translation). Lab Med 1992; 16: 412–18.

Read GF . Oestradiol assays and hormone replacement therapy. Commun Lab Med 1992; 1: 80–3.

Diver MJ . Monitoring of hormone replacement therapy. Lancet 1992; 340: 1471.

Mashchak CA Lobo RA . Comparison of pharmacodynamic properties of various oestrogen formulations. Am J Obstet Gynecol 1982; 144: 511–18.

Whitehead MI Godfree V . Your questions answered. In: Hormone Replacement Therapy. Churchill Livingstone, 1992: 165–78.

Garnett T Studd JWW Henderson A Watson N Savvas M Leather A . Hormone implants and tachyphylaxis. Br J Obstet Gynaecol 1990; 97: 917–21.

Savvas M Studd JWW Fogelman I Dooley M Montgomery J Murby B . Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. BMJ 1988; 297: 331–3.

Studd JWW Savvas M Waston N Garnett T Fogelmann I Cooper D . The relationship between plasma oestradiol and the increase in bone density in post menopausal women after treatment with subcutaneous hormone implants. Am J Obstet Gynecol 1990; 163: 1474–9.

Slemenda C Hui SL Longcope C Johnston CC . Sex steroids and bone mass. A study of changes about the time of menopause. J Clin Invest 1987; 80: 1261–9.

Nilas L Christiansen C . The pathophysiology of peri and post menopausal bone loss. Br J Obstet Gynaecol 1989; 96: 580–7.

Steinberg KK Titulaer LW Freni DePuey EG Miller DT Sgoutas DS Coralli CH Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab 1989; 69: 533–9.

Alden JC . Osteoporosis—a review. Clin Ther 1989; 11: 3–14.